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In Papers I  and III of this series,  quantitative  relationships between anti- 
body,  qulnidine,  and  platelets  in various in  vitro  reactions  were described. 
This  provided a  basis for evaluating  in  vivo  relationships  between these re- 
actants when test doses of quinidine were given to patients with the antibody 
of quinidine  purpura.  Regulated  test  doses of quinidine  were given  to  one 
patient  at  intervals  during  the  period  of decline  of a  high  serum  antibody 
concentration present after quinidine purpura, and to another patient after anti- 
body was present following  an  anamnestic  response to qulnidine  given as a 
diagnostic test for sensitivity. 
By comparing  the  in  vivo  conditions  which  resulted  in  thrombocytopenia 
with  the in vitro  conditions necessary for various antibody reactions,  the in 
vivo reactions which led to a decrease in circulating platelets could be deduced. 
Results  of the  present  work appeared  to  be pertinent  to  other diseases  of 
sensitivity.  In light of  these  results,  a  detailed interpretation  of the  patho- 
genesis  of idiopathic thrombocytopenic purpura  (ITP),  I which had been con- 
sidered to be a  disease of sensitivity, is presented. 
Materials and Methods 
All reagents and techniques used are described in Papers I  and III of this series. 
Case Reports 
Case 1, E. T. S., a white female, age 74, was admitted to the United States  Naval  Hos- 
pital, Bethesda, Maryland, on March 8, 1955, for weakness associated with a rapid and irreg- 
ular pulse. She had had similar episodes previously, the first about 6 years prior to admission, 
with recurrences at 3 to 6 month intervals. About 3 years prior to admission, she was advised 
to take quinidine at the onset of such attacks and had taken a single tablet of 0.2 gin. quini- 
*Present  address:  National  Institutes  of  Health,  Bethesda,  Maryland. 
* ITP, idiopathic thrombocytopenic purpura. 
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dine sulfate on about five occasions with prompt relief of symptoms. Between 3 and 7 p.m. 
on the day of admission she had taken two quinidine tablets, each containing 0.2 gun. quini- 
dine sulfate, and was admitted at 10 p.m. because she had not obtained the customary relief 
with this medication. She had taken no quinidine for 4 to 6 months prior to the day of admis- 
sion, and had never taken any other drug except for an occasional aspirin. She had never had 
any allergic disorder. 
The chief physical findings on the evening of admission were moderate cardiac enlargement, 
irregularity of the pulse typical of auricular  fibrillation, and  a  moderate tachycardia.  The 
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FIG. 1.  Case 1, platelet counts following onset of qu~dme purp~ra. Day 1 was the morn- 
ing after admission when purpura was first noted, approximately 18 hours after therapeutic 
doses of qulnidlne. The platelet count in subsequent months of observation remained stable 
at  approximately  3  X  105/ram. a. 
physical examination was otherwise normal. No abnormalities of the skin or mucous mem- 
branes were  noted. An electrocardiogram showed auricular  fibrillation.  Digitalization  with 
digitoxin  was begun and nembutal was given as a sedative.  No other drugs were given. 
The following  morning, March 9, the patient felt  well,  her pulse was regular  at 78 per 
minute, and an electrocardiogram was normal except for digitalis  effect.  However, at this 
time, the patient had numerous petechial  hemorrhages in the skin over the lower abdomen 
and on the extremities,  increasing  in number peripherally.  There were also  numerous hemor- 
rhagic  bullae  on the mucous membranes of the mouth and pharynx and there  was bleeding 
from the gums. The peripheral  blood on the morning of March 9 contained 500 platelets/ 
ram.  s,  8,350  white  cells/ram,  s  with a normal differential,  and 12.7  gin.  per cent of  hemoglobin. 
The bleeding time (forearm) was greater than 20 minutes, the clotting  time was normal, 
and there  was no clot  retraction  in 1 hour. A diagnosis  of quinidine  purpura was established 
by the presence of  marked platelct  agglutination  in  mixtures of the  patient's  plasma, platelet- N.  RAPHAEL SHULMAN  713 
rich plasma from normal individuals, and quinidine sulfate solution; and the absence  of agglu- 
tination in  mixtures in which  saline  was substituted for quimdine  solution. 
Purpura extended during the first 2 hospital days, but on the 3rd day there were no new 
petechiae or ecchymoses, and by the 4th day the hemorrhagic  bullae in the mouth had dis- 
appeared and ecchymoses were fading in spite of the fact that the platelet count had not yet 
risen above 8,000/ram. s. A bone marrow aspiration taken on the 4th day was normal with re- 
spect to the myeloid and erythroid series and megakaryocytes were normal in number and 
morphology. 
The patient's white count and differential  remained normal throughout.  The total pro- 
tein and albumin:globulin ratio were normal at the time of her first hospital admission and a 
serum electrophoretic pattern was normal 3 months later. A patch test (1) done 3 months 
after her first admission  by placing a gauze pad soaked in a saturated aqueous  solution of 
quinidine giuconate on the forearm showed no petechiae after 32 hours, and a capillary  fragil- 
ity test did not produce petechiae over the area of the patch. Fig. 1 shows the platelet counts 
obtained on the patient during and after quinidine  purpura. 
Case 2, R. A. K., a white female, age 62, was admitted to the Clinical Center,  National 
Institutes of Health, Bethesda, Maryland, on August 20,  1956, for evaluation of digitalis 
therapy in controlling recurrent episodes of paroxysmal auricular tachycardia. She had taken 
quinidine for paroxysmal tachycardia intermittently over a period of several years up to 3 
years prior to admission, at which time she had developed extensive ecchymoses and petechiae 
which cleared spontaneously over a period of several days after the drug was stopped. Quini- 
dine sensitivity was suspected  but not proven and she had not taken quinidine for 3 years. 
When admitted she had no detectable antibody in her serum by complement fixation, platelet 
agglutination, or inhibition of clot retraction tests. 
Results of Tests in Vivo 
Case 1.-- 
(a) Antibody  concentration during 2 year period of observation. Fig. 2  shows 
the  concentration  of antibody in  units/milliliter determined by complement 
fixation and the titer determined by platelet agglutination over a  2 year period 
beginning with the initial episode of quinidine purpura. Antibody concentration 
determined on serum obtained the morning purpura was first noticed was 50 
units/ml.,  and  it rose  within  a  3  week period  to  levels in  the  order of 300 
units/ml. The subsequent decline of antibody concentration and the antibody 
response to test doses are charted. 
(b)  Test doses of quinidine  and quinine  during  the 7th month of observation. 
The patient was readmitted to the hospital 7 months after quinidine purpura 
had occurred to determine the in vivo effects of quinidine. Antibody concentra- 
tion in the patient's plasma at this time was 40 units/ml. 
It was known that complement fixation, the most sensitive test of antibody 
activity,  would  occur  minimally with  this  concentration  of  antibody  when 
quinidine concentration was in the order of 10  -6 ~  (see Paper I). It was con- 
sidered that in vivo administration of quinidine in amounts sufficient to produce 
approximately this  concentration  of qninidine in  the patient's plasma might 
provide a safe procedure for determining the effects of quinldine on the level of 
circulating platelets. If the in v/vo concentration of administered quinidine were 714  TMMUNOREACTIONS  INVOLVING  PLATELETS. IV 
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FIG. 2. Case I, antibody concentration in patient's  serum over a 2 year period.  Antibody 
concentration in units/milliliter  determined by complement fixation  as described in Paper I. 
Agglutination titers  show the  range of  the  reciprocal  of  serum dilutions  producing 1-{-  platelet 
agglutination  in i hour in  the standard agglutination  mixture described  in  Paper III.  The drug 
dose  which initiated  purpura  was 5.1 X  I~  moles of  quinidine  sulfate,  (C~0H=~O=N2)s" HsSO4. 
2H=O, or 10.2  X  10  -~ moles of quinidine.  First test  dose during 7th month of observation, 
2.4 X  10  -6 moles of quinidine; second test  dose beginning of 16th month, 1.2 X  I0-~ moles 
of cinchonine -{- 1.7 X  10  -6 moles of qninidine; third test dose, 22nd month, 3.8 X  I0  -s 
moles of quinidine. 
determined only by dilution in the patient's plasma volume (assumed to be 2 
liters), approximately 1 mg. of quinidine gluconate would have to be given to 
produce a  10  -6 ~  concentration. 
Qninidine ginconate was given intravenously at a concentration of 35 ~,/ml. in 5 per cent 
glucose in water (10  -~.m ~ quinidine) and at a rate of 1.5 ml./minute (10  --4 milllmols/minute). 
After the patient had received 0.63 rag. of qninidine gluconate  over a period of  12 minutes, 
the platelet count had fallen from the control value of 3.2 X  105/mm) to 1.75 X  106/ram) N.  RAPHAEL  S~  715 
(Fig. 3).  The infusion was stopped after it had been rnnning for a  total of 24 minutes during 
which time 1.26 rag. of quinidine giuconate had been given. Platelets were at the lowest level, 
0.77 X  106/ram.  s, when measured one-half hour after the infusion was stopped, and had  re- 
turned to 2.0 X  105/ram.  s within the next 5 hours.  One day later platelets were still lower 
than control values. 
White counts done at the same time as the platelet counts showed no sig- 
niticant variation.  The  patient  did not  develop symptoms and  a  capillary 
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FIe. 3.  Case 1, changes in platelet count during 7th month tests. See text. Platelet counts 
were taken from freely flowing blood from a finger puncture using 4 pipettes and 8 chambers 
for each count. Three individuals each counted several chambers, and the average of the re- 
sults of all counts is plotted. Control values were obtained from two 8 chamber counts per- 
formed within 1 hour before the infusion was started. The rate of intravenous flow was regu- 
lated with a calibrated mechanical pump. 
fragility test and bleeding time done when platelets were at the lowest level 
were normal. A clot retraction test done as in Paper III, but without adding 
quinidine, gave 22 per cent free fluid when platelets were at the lowest level, 
and 45  per  cent free fluid 1 hour later.  Platelets observed in  the  patient's 
plasma taken at the same time as samples for clot retraction appeared normal 
in morphology. They did not agglutinate in 16 hours without added quinidine 
but  showed rapid  agglutination on addition of an optimal concentration of 
quinidine  (see  Paper  III).  The concentration of antibody in serum samples 
taken at the same time as platelet counts on the day of the infusion did not vary 
signiticanfly from the pre~infusion value of 40  units/ml. 716  TM%~UNOREACTIONS  INVOLVING  PLATELETS.  IV 
Quinidine dihydrochloride given 2 days after the test dose of quinidine at the 
same molar concentration and rate of administration produced no effect on the 
platelet count. 
(c) Test doses of cinchonine, quinidine, and cinchonidine during the I6th month 
of observation. When  antibody concentration  in  the patient's serum  had  de- 
creased  to  18  tmits/ml.,  the  effects  of  intravenous  cinchona  alkaloids were 
observed again (Fig. 4). Cinchonine, which was found to be as effective as qui- 
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FIo.  4. Case  1, changes  in  platelet  count  during  16th  month  tests.  See  text  and  legend 
Fig.  3.  The  height  of  the  stippled  block  is  proportional  to  the  rate  of  drug  administration 
nidine in in vitro tests (see Papers I  and HI) was given intravenously at a con- 
centration of 35  "y  of  cinchonine  sulfate/ml,  in  5  per  cent  glucose  in  water 
(10  ~.~1  ~  cinchonine  sulfate,  10  -~ ~r cinchonine)  and  at  a  rate  of  0.8  ml./ 
minute  (0.8 X  10  -~ millimols cinchonlne/minute). 
After the patient had received 0.84 rag. of cinchonine sulfate over a period of 30  minutes, 
the platelet count had fallen from a control value of 3.11 X  10~/mmY to 2.44 X  10~/mmY, a 
very significant difference with the method of platelet counting  used (2).  The infusion was 
stopped and the platelet count remained at approximately the same level for 1 hour.  At this 
time the infusion was started again at the same rate of administration. Within 30 minutes 
after the infusion  was restarted, the platelet count had fallen further to  2.0 X  10=/ram.  s. 
It remained at approximately that level during the 2 hour period in which an additional 4 
rag. of clnchonine sulfate was given. After the infusion was stopped, the platelet count re- 
turned  to  2.8 X  10~/mm.  a within  2~  hours. N.  RAPHAEL  SR'IYLMAN  717 
There was no significant change in antibody concentration in serum samples 
taken at the same time as platelet counts and no significant variation in white 
cell count. The patient had no symptoms. 
One day after cinchonine was given, the patient was given a total of 14.5 rag. 
of cinchonidine sulfate intravenously over a 1 hour period (6.5 X  10  -4 millimols 
cinchonidine/minute) without effect on the platelet count. 
Two days after cinchonine was given, at which time antibody concentration 
was still approximately 18 units/ml., quinidine gluconate at a concentration of 
40 7/ml.  (10  -~'n M) was given intravenously at a rate of 1.2 ml./minute (0.9 
X  10  --4 miUimols/minute). 
During continuous administration at this rate for 1~ hours, the platelet count decreased in 
approximately the same manner as it had when a  similar amount of cinchonine was given. 
The rate of infusion was then increased approximately threefold to 2.5  X  10  -4 milllmols/ 
minute, and within 30 minutes the platelets had fallen to 1.5 X  105/ram.  a.  The infusion was 
given at the increased rate for a total of 37 minutes before being stopped, and 40 minutes after 
it was stopped, the platelet count was 0.43 X 105/mm.  s. Within 1~ hours after the infusion 
was stopped, platelets had begun to rise and continued to rise for the next 7 hours, but then 
remained stable for at least 3 days at a level between 1.4 and 1.7 N 105/ram.  *  before  returning 
to normal. 
The patient had no symptoms, and a capillary fragility test and bleeding time 
done when the platelet count was at its lowest level were normal. Platelets ob- 
served in the patient's plasma taken at the same time as platelet counts had 
normal morphology and did not agglutinate when incubated for 16 hours with- 
out added quinidine but agglutinated in all samples on addition of quinidine 
at optimal concentration. The serum sample taken at the time the quinidine 
infusion was stopped, when the in vivo concentration of quinidine would have 
been highest, did not fix complement in the presence of an optimal concentra- 
tion of platelets from a normal donor unless quinidine was added. The comple- 
ment content of this serum sample did not differ signiticantly from that of a 
serum sample taken just prior to the test dose. Antibody concentration meas- 
ured in all samples taken at the same time as platelet counts on the day of the 
test dose did not vary significantly from 18 units/nil.  Two weeks  after this 
series of tests antibody concentration in the patient's serum had risen to 42 
units/ml. 
(d) Test dose of quinidine, 22nd month of observation.--At  this time antibody 
concentration in the patient's serum was 8 units/ml. In vitro tests showed com- 
plete inhibition of clot retraction on addition of an optimal concentration of 
quinidine to the patient's blood and 1+ agglutination when optimal qulnidine 
was  added  to  the patient's  platelet-rich plasma  or to mixtures  of platelets 
resuspended  in  the  patient's  undiluted  serum  (see  Paper  Ill).  No  platelet 
agglutination  occurred within 1 hour in  agglutination  mixtures  in which the 
patient's serum was diluted as much as twofold. 718  TM-MUNOREACTIONS INVOLVING PLATELETS. IV 
Qninidine gluconate at a  concentration of 35 ~//ml.  was given at a  rate of 
1.6  ml./minute  (1.1  X  10  -~ millhnols/minute)  continuously for  a  period  of 
31./~ hours except for the 12 minute interruption indicated in Fig. 5. The platelet 
count fell  within  30  minutes  from the  control value  of 2.8  X  105/ram?  to 
approximately 2.25  X  10s/ram.  8 at which point it remained stable. 
PLAT'ELETS  xlO  5 
3.O 
2.5 
1.5 
LO 
0.5 
~  OUfNio~s¢  t  164  lUlILLIMOLES/MIN, 
.............  AV~  ~  ,  I'  7~  HOURS  0  I  3  5  7  9  II  24  48  9 
Fzo. 5.  Case 1, changes in p]atelet count during 22nd month test.  See text and legend, 
Fig. 3. After the infusion had been Dmn{n~; for 50 minutes, it was stopped for a 12 minute 
period because it appeared, from cursory  inspection of a frestgy flooded  counting chamber, 
that the platelet count was going to be much lower than it proved to be after platelets had 
settled. 
The rate of infusion of quinidine was then increased to 2.4 ml./minute for 15 minutes,  and 
to 3.2 ml./minute  (2.2 X  10  -4 millimols/minute)  for 70 minutes.  With the increased  rate 
of infusion the platelet  count decreased further to approximately  106/ram.  s and remained 
at that level for approximately  1 hour after the infusion was stopped. There was a biphasic 
return of platelets to the control level over a period of 3 to 4 days. 
Clot retraction tests without added quln~dine gave a value of 59 -4- 4 per cent 
free fluid on 4 pre-infusion samples, 49 4- 7 per cent on 6 samples taken in the 
2~  to3~  hour interval during the infusion, 31 ~- 3 per cent on 3 samples taken 
at the tLme the infusion was stopped,  and 36 4- 3 per cent on samples taken 
1 hour later. The concentration of antibody in sera obtained at the same time 
as the platelet counts on the day quinidine was given did not vary significantly 
from 8 unlts/ml.  Quinidine content in the serum sample taken at the time the N.  RAPHAEL  SHUI,MAN  719 
infusion  was  stopped  was  insufficient  to  cause  complement  fixation  in  the 
presence of an optimal concentration  of added platelets. 
Case 2.-- 
(a)  First  tea  dose  of quinidine.  The  patient  had  no  detectable antibody 
activity in her serum at the time of the first test dose. Qulnldine gluconate at a 
concentration of 1.4 mg./ml,  in 5 per cent glucose in water was given intra- 
venously at a  rate of 2.0 ml./minute  (53.4  X  10  -4 millimols/mlnute)  for 78 
minutes, the total amount received being 218 rag. The plasma quinidine con- 
centration had become sufficiently high to produce a 0.06 second prolongation 
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FIG. 6.  Case 2, antibody concentration in patient's serum following test doses of qui~ciiae. 
See tezt. Patient had taken no quiaJd~e for 3 yeats prior to the first test dose. 
of the Q-T interval  of the  electrocardiogram  by the  time  the infusion was 
stopped. The patient had no symptoms and there was no signficant variation in 
platelet count during or after the infusion. 
There was no detectable antibody in the patient's serum for 2 days after the 
infusion, but by the 3rd day antibody was measurable at a concentration of 0.2 
units/ml.  (see Fig. 6). Antibody concentration continued to rise over the sub- 
sequent 2 weeks and by the 18th postinfusion day was 2.6 uuits/ml. Prior to the 
18th postinfusion day inhibition of clot retraction did not occur when an optimal 
concentration  of quinidine  was added  to the patient's  whole blood; and  ag- 
glutination of platelets did not take place in the patient's platelet-rich plasma 
over a period of 16 hours in the presence of an optimal quinldine concentra- 
tion. The same tests done on the 18th day gave partial inhibition of clot re- 
traction  (26 per cent free fluid); and  ±  to  1+  platelet agglutination  in the 
patient's platelet-rich plasma after an incubation period of 16 hours, but no 
agglutination within 1 hour. 
(b) Second test dose of quinidine.  Twenty-seven days after the first test dose 720  IMMUNOREACTIONS  INVOLVING  PLATELETS.  IV 
(see  Fig.  6),  when  antibody  concentration  was  1.5  units/ml,  and platelet  ag- 
glutination  and inhibition  of clot retraction  could no longer be detected  by in 
~ilro  tests~  quinidine  gluconate  at  a  concentration  of 0.48  mg./ml,  was given 
intravenously  at  an  initial  rate  of  0.7  ml./minute  (6.5  X  IO  q  millimols/ 
minute),  the rate being increased in a  stepwise fashion shown in Fig.  7. 
Within the 1st hour, during which time the patient  received  40  rag. of quinidine  gluco 
nate, the platelet count fell from a control value of 2.9 X  lOi/mm,  a to  1.95  X  lOi/mm~  s 
and rems~ned at approximately that same level in spite of the fact that an additional 70 rag. o 
FIe.  7. Case  2,  changes  in  platelet  count  during  second  test  dose  of  quinidine.  See  text  and 
legend,  Fig.  3. 
quinidine  gluconate  was given  in  the  next  40 minutes.  The platelet  count  was still  approxi- 
mately  2.0  X  106/ram.  s  3~ hours  after  the  infusion  was  stopped,  and the  following  morning 
it was at a normal level.  The patient  did not have any symptoms and the maximum pro- 
longation  of  the  Q-T interval  of  the electrocardiogram  was 0.02  second  at  the  time  the  infu- 
sion  was  stopped. 
Eight days after  the  second test  dose, antibody concentration in  the  patient's 
serum was 5 units/ml. At this  time complete inhibition of clot  retraction (6.7 
per cent free  fluid)  occurred when quinidinc was added to her whole blood and 
lq- platelet  agglutination occurred within I hour in the patient's  platelct-rich 
plasma with added quinidine. Within 17 days after the second test  dose anti- 
body concentration had begun to decline.  There was only partial  inhibition  of 
clot  retraction (23 per cent free  fluid)  when quinidine was added to her whole N. RAPHAEL  SHULMAN  721 
blood, and platelet agglutination  was  not  evident within  1 hour in  the pa- 
tient's platelet-rich plasma with added qulnidine. 
Measurement  of in vivo Quinidine Concentration.-- 
The lowest rate  of quinidine  administration  used  to produce  thrombocy- 
topenia in Figs. 3 to 5 was approximately 10  -4 mfllimols/minute. The plasma 
ouinidine concentrations produced at this dose rate are shown in Table I. 
TABLE I 
Infusions of quinidine gluconate at a  concentration of 35 T/ml. in 5 per cent dextrose in 
water were given to two normal subjects at the dose rates indicated in the table. In each 
case the infusion was stopped after 30 minutes. The average value of  duplicate determina- 
tions of plasma quinidine concentration done at each time interval are recorded.  The varia- 
tion was no greater than 4-8 per cent of the average. 
The method of measuring quinidine was described by Udenfriend et al. (3). The drug was 
extracted from 7 ml. of alkalinized platelet-rich plasma with 15 ml. of benzene. Fluorescent 
impurities in reagent grade benzene had been removed by adsorption on silica gel columns 
and by washing with sulfuric acid. A 10 ml. aliquot of the benzene extract was then extracted 
with 1.5 ml. of 0.1 ~ H~SO,, and the concentration of quinidine in the acid extract was deter- 
mined using an Aminco-Bowman spectrophotofluorometer at  an activation wavelength of 
340 m# and a  fluorescence wavelength of 440 m#.  Recovery of quinidine gluconate from 
plasma and whole blood was 87 4- 10 per cent when the amounts added in ~itro  produced 
plasma concentrations ranging between 0.005 to 0.14 T/ml.  (9.6 ×  10  -9 to 2.7 ×  10s ~). 
Min. after 
infusion started 
5 
10 
20 
30 
40 
50 
Plasma quinidine concentration 
Dose rate: 0.92 X 10-1  millimols/min. 
3.44 X  10-  9t' 
9.77  X  10"-9 M 
2.48  X  l0 s 
2.62  X  1OS~ 
9.20 X  10  -9 M 
Dose rate: 1.12  X 10-4  millimols/min, 
2.18 X 10-  s ~' 
2.54 X 104~ 
3.33 X 10  -~ M 
2.74X 10-SM 
DISCUSSION 
1.  Factors of Significance  in the Development of Thrombocytopenia  Based on 
Observations of Quinidine  Purpura.---Observafions  made  on  the patient  who 
developed quinidine purpura suggested that capillary abnormalities which lead 
to hemorrhagic manifestation  are  a  consequence of  thrombocytopenia, and 
that thrombocytopenia may exist for a period of time before abnormal capillary 
permeability develops. 
In view of the high concentration of antibody in the serum  of the patient the 
morning after admission  (50 units/ml.) and the large amount of quinidine  (200 rag. 
quinidine  sulfate)  which  the patient had taken approximately 7 hours and again  3 722  I'M'MUNOP~EACTIONS  INVOLVING  PLATELETS.  IV 
hours prior to admission, marked thrombocytopenia  had no doubt been present the 
evening of admission in spite of the fact that purpuric  manifestations  were not yet 
evident at that time.  Antibody concentration  in the patient's plasma  at the time 
quinidine was taken therapeutically  must have been approximately the same as that 
measured  in serum taken the following morning because an induction period  of 2 
to 3 days was observed before antibody concentration  rose following all subsequent 
test doses. Even if the concentration  of antibody had been as low as 8 units/m1, at 
the  time  quinidine  was  taken  therapeutically  profound  thrombocytopenia  would 
have developed within an hour after taking quinidine  in view of  the rapidity of 
quinidine absorption  (4) and the rapidity of development  of thrombocytopenia  fob 
lowing test doses of quinidine (e.g., Fig. 5). 
It would appear,  therefore, that thrombocytopenia preceded the develop- 
ment of purpura by a  number of hours. In other reported cases of purpura 
following therapeutic or test doses of quinidine it appears that thrombocyto- 
penia  preceded  hemorrhagic manifestations by a  similar  time  interval  (5). 
Furthermore, profound effects on the level of circulating platelets were ob- 
served in the present series of tests without effects on capillaries as judged by 
the tourniquet test, bleeding time, and occurrence of spontaneous hemorrhage. 
In these instances thrombocytopenia was apparently insufficient or  too tran- 
sient to result in capillary damage. It does not seem necessary to consider that 
antibody damages  blood  vessels  or  endothelium by  a  direct  reaction,  and 
attempts to demonstrate such a  reaction in  vitro  have been unsuccessful (see 
Paper III). 
A  question remains as to whether megakaryocytes as well as platelets  are 
affected by the antibody. In the patient with quinidine purpura there were 
practically no platelets in the circulation for 4 days before a  gradual rise in 
platelets occurred (Fig. 1); and in view of the rate at which quinidine is ex- 
creted (4), the stimulus for thrombocytopenia had no doubt persisted for the 
entire 1st day. Hemorrhagic manifestations were clearing at least 2 days before 
there was a significant rise in platelets, and it may be considered that platelets 
were being utilized for hemostasis during this period. Craddock et a/. (6)  ob- 
served a 3 to 4 day period of delay before circulating platelets increased follow- 
ing production of thrombocytopenia in dogs by a technique involving mechan- 
ical removal of platelets extracorporeally. They interpreted the delay as re- 
flecting the period of time required for platelets to develop from megakaryocytes 
after all available platelets had been released from mature megakaryocytes and 
other platelet stores. In view of the observations of Craddock eta/., the  ob- 
served delay in return of platelets in this patient would be expected even if 
megakaryocytes had been functioning at maximum capacity during the course 
of the disease. Bone marrow samples taken in this case and a number of other 
reported cases  (review by Bolton and Dameshek (7))  at the height of  drug 
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increased number, of megakaryocytes; and any morphologic  changes  observed 
in megakaryocytes have been consistent with immaturity of hyperplastic ceils 
described by Craddock et aL Moreover, it has been observed in vitro  that anti- 
bodies which affect platelets do not necessarily affect megakaryocytes (8).  It 
therefore  appears  that  megakaryocytes were  not  destroyed  and  that  their 
function was not impaired during drug purpura.  Any changes in the level of 
circulating platelets produced by the antibody in the presence of the drug may 
be interpreted in this light. 
2.  Factors of Significance  in the Development  of Thrombocytopenia  Based on 
Observations  during Test Doses.--The amount of quinidine administered during 
the first test dose in Case 1 was chosen to assure that the plasma concentra- 
tion would not exceed 10  --6 u, the concentration at which minimal complement 
fixation occurred in vitro. After 0.63 rag. of quinidine gluconate had been given 
over a period of 12 minutes, a decrease of 1.45 X  10  ~ platelets/mm) was ob- 
served (Fig. 3), but it is evident that platelets had begun to decrease before this 
time. The concentration of quinidine present in plasma at the time platelets 
first began to decrease in the circulation was less than 10  --s ~  (see Table I) and 
did not reach levels higher than 3.3 X  10-  s u  during the entire test. Thus the 
in vivo concentration of quinidine which caused thrombocytopenia was much too 
low to cause complement fixation or platelet agglutination. Blood samples taken 
during three of the tests at the time of marked thrombocytopenia when in vivo 
quinidine concentration was highest contained insufficient quinidine to produce 
measurable in vitro complement fixation,  platelet agglutination, or inhibition of 
clot retraction  (other than  that  consistent with  the degree of thrombocyto- 
penia). This is further evidence that decreases in circulating platelets occur in 
vivo when quinidine concentration is too low to cause the various in vitro effects 
which have been considered to be of importance in the pathogenesis of thrombo- 
cytopenia. 
The  observation  that  no  significant  decrease  in  antibody  concentration 
occurred in the patient's plasma during the tests suggested that only minimum 
amounts of antibody were attached to platelets at the time thrombocytopenia 
occurred.  Considering  the  amount of  antibody which platelets  adsorb  even 
when quinidine concentration is too low to cause complement fixation  (Paper 
I,  Fig.  6),  and  the number of platelets available for reaction  with antibody 
during the tests, if sufficient antibody had been adsorbed to cause complement 
fixation during  these tests, a  decrease in antibody concentration would have 
been measurable. It was unlikely that constant antibody concentration was the 
result of continual release of antibody from sequestrated or destroyed platelets, 
for it was shown in Paper I  that platelet fractions adsorb antibody as well as 
intact platelets. The amounts of antibody attached to platelets when thrombo- 
cytopenia occurred were evidentlyless than the measurable amounts attached to 
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fixation.  The fact that platelets adsorbed very little antibody does not imply 
that platelets were not affected by the minimal amount of antibody which must 
have attached in dvo. Although not measurable, the amount of adsorbed anti- 
body nevertheless could have been consistent with the presence of many anti- 
body molecules per platelet; and it has been shown that the attachment of as 
few as 60 antibody molecules per cell may alter properties of cell membranes 
sufficiently to cause reactions such as agglutination (9).  The development of 
thrombocytopenia was no doubt due to alteration of platelets by attachment of 
antibody, but the mechanism of removal of platelets from the circulation may 
only be surmised.  It is possible that changes in the surface properties of platelets 
produced by attachment of antibody may have made platelets more susceptible 
to sequestration by physiologic  surface phenomena such as phagocytosis (10) 
in capillary beds or sinusoids of such organs as the spleen, liver, and lungs. 
The initial in d~o decrease in platelets during other tests in Case 1 (Figs. 4 
and 5) occurred when qu{n{dine was given at approximately the same rate and 
for a similar period of time as during the first test, but decreases in platelets 
were less when plasma antibody concentrations were lower. A marked fall in 
platelets resembling that which occurred when antibody concentration was 40 
unlts/ml. (Fig. 3), occurred in the presence of 18 (Fig. 4) and 8 (Fig. 5) units of 
antibody/ml, only when the rate of administration of quinidine was increased 
two- or threefold. The test dose given to Case 2, when antibody concentration 
was 1.5 units/ml., produced an initial decrease in platelets only when a com- 
paratively high rate of quinidine administration  was used, but then produced 
no  further  decrease  in  platelets  even  when  quinidine  was  administered  at 
greatly increased rates. In view of the electrocardiographic changes at the end 
of this test, the maximum plasma quinidine concentration attained was in the 
order of 10  -6 ~  (4). Thus there was an inverse relationship between antibody 
concentration  and  the  amount  of quinidine  necessary to produce thrombo- 
cytopenla. At concentrations of antibody as low as 8 units/ml,  complete re- 
moval of circulating platelets appeared to be possible if sufficient quinldine were 
given; but when antibody concentration was quitelow (1.5 units/ml.), the degree 
of decrease in platelets which could be produced was limited by antibody con- 
centration rather than quinidine  concentration. 
At appropriate rates of administration of quinidine the platelet count fell but 
then became stable at a lower level in the face of continued administration of 
quinidine at the same rate (Figs. 4, 5, and 7). The level of circulating platelets 
during test doses therefore appeared to reflect a balance between the rate of plate- 
let removal and supply. When antibody and quinidine  were present in sufficient 
concentration, the rate of removal of platelets could completely overcome the 
rate of supply (Figs. 4 and 5). The rate of return of platelets to the circulation 
appeared to be related not only to the severity of the thrombocytopenia but 
also to its duration (compare Figs. 3 to 5). After slight thrombocytopenla there N.  RAP}tAEL  Stt'ULMAN  725 
was a comparatively rapid  return tO normal levels; e.g., Fig. 4 (cinchonine curve) 
and Fig. 7. Part of the delay in return of platelets in Fig. 7 was no doubt related 
to persistence of a  significant concentration of quinidine after a comparatively 
high dose. Following more marked or more prolonged thrombocytopenia, there 
was a prolonged and biphasic recovery  of platelets as seenin Fig. 3, the quinidine 
curve of Fig. 4, and Fig. 5. Biphasic recovery consisted of an initial rapid in- 
crease in platelets within several hours followed by a period of stabilization at a 
level lower than normal for 1 to 2 days before a return to pre-infusion values. 
It is probable that platelets reappearing in the immediate postinfusion period 
were  supplied  mainly  from pre-existing stores  in  spleen  and  lung  and  from 
megakaryocytes still capable of releasing platelets, as was suggested by Crad- 
dock (6). There may also have been a contribution by platelets released from 
sequestration after detachment of antibody when quinidine concentration de- 
clined. The second phase of recovery may have been due to the period required 
for  maturation  of hyperplastic  megakaryocytes after  the  ability  of mature 
megakaryocytes to  release  platelets  and  platelet  stores  were  exhausted  (6). 
The extent of delay before platelets returned  to normal probably reflects the 
over-all number of platelets destroyed as a  result of sequestration during test 
doses. Further observations of effects of test doses will be necessary before more 
precise interpretations can be made. 
3. A Suggested Method of Performing Test Doses in Patients with the Antibody 
of Drug Purpura.--- 
Because observations of responses  to test doses will be made for their diagnostic 
as well as their experimental value, the experience  gained in performing the current 
series  of  tests requires  further  comment. When antibody concentration  was  quite 
low (in the order of 1.5 units/ml.), no platelet agglutination or inhibition  of clot re- 
traction was detected in vitro, and  an amount of quinidine  equivalent to a  thera- 
peutic dose produced only a moderate thrombocytopenia of no clinical  significance. 
When  antibody concentration  was  sufficiently  high  to produce detectable platelet 
agglutination  and  inhibition  of dot  retraction,  severe thrombocytopenia could  be 
caused by much lower doses of quinidine. 
If the concentration of antibody were known, the amount of quinidine  necessary 
to produce a desired  degree of thrombocytopenia could  be chosen with reference  to 
the tests described  above. If antibody concentration were not known,  10  -4 ,s quin- 
idine given at a rate of 1 ml./minute would be a safe initial test dose. If there were 
no evidence of thrombocytopenia developing within  10 to  15 minutes, the amount 
of quinMine  given could  be doubled each  15  minute period until as much as 3  × 
10  -a millimols/minute were given. Failure of platelets to decrease  at this rate of ad- 
ministration of quinidine  would be evidence that no clinically  significant  amount of 
antibody was present.  A  single  negative  test would  not rule  out  the  existence  of 
sensitivity (see Fig.  6).  A negative test should  be followed by at least one repeated 
test 2 to 3 weeks later. In order to assure an adequate anamnestic antibody response 
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given to the patient with impunity several  hours after the initial negative intra- 
venous  test;  for  the  degree  of  antibody  response  appeared  to  be  related to 
the amount of quinidine given. 
Performance of test doses with intravenous quinidine as described appears to 
be a  safe procedure. Even if marked thrombocytopenia is produced with low 
doses of quinidine when antibody concentration is high, the quinidine is rapidly 
dissipated in dvo, and thrombocytopenia  is so transient that significant capillary 
fragility does not  develop.  The suggested  technique for performing in  dro 
tests is meant only as a guide, for responses of different individuals may not be 
the same. Quantitative relationships between in dtro and in dro reactions may 
be similar in the case of other drugs causing thrombocytopenia. 
4.  Implications of Observation on Drug Purpura in ITP.-- 
The syndrome of ITP is thoroughly described  and current interpretations of its 
pathogenesis  presented in references 11-13. ITP is daaracterized  by a variable clini- 
cal  course  with  spontaneous  remissions  and  relapses,  an  inconstant  response  to 
splenectomy or the  adminfstration of adrenosteroids  mad  adrenoeorticotropic hor- 
mone (ACTH), and discrepancies between degree of hemorrhagic manifestations  and 
the level of circulating  platelets and  between the severity of the disease  and  the 
presence  of an in vitro platelet agglutinin  or an in vivo thromboeytopenic factor. 
Hypotheses  concerning  the  role  of  megakaryoeytes, platelets,  capillaries,  spleen, 
antibodies,  hormones,  and  their interactions in the pathogenesis  of ITP have in- 
duded  the following possibilities:  (a)  direct destruction of platelets by a  "lytic" 
antibody,  (b)  removal of  "sensitized" platelets  by  the  spleen,  (c)  destruction of 
megakaryocytes by  antibody,  (d)  inhibition  of  megakaryocyte maturation  by  a 
splenic hormone, (e) production of antiplatelet antibodies  by the spleen, (f) produc-  - 
tion of a  capillary-fragility  factor by the spleen,  (g)  independent effects on capil- 
laries  and platelets by antibodies  or hormones,  and  (k)  combination  of several of 
these possibilities. 
If it is assumed that in ITP an antibody attaches to platelets and leads to throm- 
bocytopenfa in a manner similar to that described in the present work, then a more 
detailed  interpretation of  the  pathogenesis  of ITP  and  its puzzling  attributes is 
possible. 
Antigenic stimuli in ITP could be simple molecules (haptenes)  which are ingested, 
formed metabolically,  or produced by infectious agents,  in which case the antibody- 
haptene-platelet complex formation might be similar  to that in drag purpura (see 
Paper I). It would be possible, however,  for the antigen to be a protein molecule 
without an associated haptene, the antigen being adsorbed by platelets in combina- 
tion with the antibody it provokes. This possibility is suggested by the observations 
of Bounameaux and Lecomte (14) concerning the agglutination  d  platelets by non- 
specific antigen-antibody complexes. Variations  in degree  and persistence  d  anti- 
body response  or in relative concentration of haptene (or other types of antigen) 
could account for the variable picture of ITP just as the variable responses to test 
doses were related to relative antibody and haptene concentrations.  In chronic ITP 
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and antibody complexes with piatelets  would no doubt differ  in individual cases; 
and it would be impossible to predict in each ease whether amounts of adsorbed 
antibody, although sui~cient  to produce thrombocytopenia,  would necessarily  cause 
platelet  agglutination,  complement fixation,  or Luhibition  of clot  retraction  in z~tro; 
or for that matter whether measurable i~ ~tro effects  would necessarily  be associated 
with thrombocytopenia. 
If in ITP the mechanism of production of thrombocytopenia and capillary  per- 
meability were the same as it  appears to be in the case  of quinidine  purpura, clinical 
manifestations of ITP could be interpreted solely  in terms of factors  which affect 
the rate  of  sequestration  of  platclets  and the rate  of  production of  platelets  by mega- 
karyocytes. Beneficial  effects  following  splenectomy  would be due to removal of a 
very active  site  of sequestration  and would not affect  the undcrlying basis  of the dis- 
ease,  just as splenectomy benefits  hemolytic anemia due to hereditary  spherocyto- 
sis.  If no improvement followed splenectomy, it may be considered that the spleen 
was not the only important site  of sequestration.  It is possible  that the suscepti- 
bility  of platelets  to sequestration  in organs other  than the spleen  may be related  to 
the degree of  platelet  abnormality which in turn would be dependent on the amount 
or type of antibody adsorbed on platelets.  This interpretation  would account for 
exacerbations  of  ITP after  an initial  good response to splenectomy and would weaken 
the rationale  for the usually  disappointing  search  for  accessory  spleens  in recurrences. 
Following treatment with steroid  hormones or ACTH  or during spontaneous re- 
missions in ITP, disappearance of hemorrhagic manifestations  frequently antedates 
elevation of circulating  platelets  by several  days to a week. This has been inter- 
preted as indicating that the disease affects  platelets and capillaries  separately. 
However,  complete  amelioration of symptoms  without  some  subsequent  rise in 
platelets  does not occur frequently and is not so well  documented. Furthermore,  it 
appears  that  increased production  of platelets following any  thrombocytopenic 
state may be evidenced first  by cessation  of hemorrhage and only later  by a rise  in 
circulating  platelets  (e.g.,  Fig. I). The lag in rise  of circulating  platelets  may be due 
in  part to increased  utilization  of  platelets  for  hemostasis after  a hemorrhagic diathe- 
sis has existed.  If this were the case, benefit  from platelet  transfusions  might be 
expected without rise  in the level  of circulating  platclets,  and we have occasionally 
observed such responses.  Since  ACTH  or steroid  hormones arc capable of increasing 
the production of other blood cells  in some disease  states  as well  as in normal in- 
dividuals (ii),  beneficial  results  of hormone therapy in ITP may be due simply to 
increased  platelet  production. Increased piatelet  production may be manifested only 
by cessation  of hemorrhage if it is just suf~cient  to match requirements for both 
hemostasis and continued abnormal sequestration,  or manifested by a concomitant 
rise  in platelets  if increased  production is sufficient  to overcome the rates  of utiliza- 
tion and sequestration.  If it is considered that  hormone therapy is only a moderate 
stimulus for platclet  production then significant  Hses in circulating  piatelets  follow- 
ing such treatment may indieate  that  the susceptibility  of platelets  to sequestration 
was only slightly  increased,  in which case successful  results  following  splenectomy 
might be more likely.  Direct effects  on the antigen-antibody system resulting  in de- 
creased antibody  formation  (15) or in interference  with cell-antibody  union (16) 
may also  be considered in accounting for benefits  of hormone therapy.  The assump- 728  r~rMUNOREACTIONS  INVOLVING  PLATELETS.  IV 
tion that a direct effect on capillaries alone accounts for cessation of hemorrhage in 
the face of persistent thrombocytopenia does not appear to be necessary. 
It has frequently been considered  that the morphologic  changes  in megakaryo- 
cytes observed in association  with ITP are indicative of cellular damage.  However, 
these morphologic changes are the same as those observed by Craddock eta/. when 
megakaryocytes were hyperplastic (6); and the same as those seen in drug purpura, 
a disease which does not appear to be associated  with megakaryocyte damage (see 
above discussion). These considerations,  in addition to the observation that a strik- 
ing rise  in platelets frequently occurs  immediately after splenectomy,  support the 
conclusion that damage  to megakaryocytes is not an integral part of ITP. 
The frequency with which initial  episodes of ITP follow acute upper  respiratory 
infections and with which exacerbations  of the disease follow intercurrent infections 
has implied that sensitization  is related in some way to infectious agents.  It is  pos- 
sible,  however,  that incidental acute infections  lead  to  temporary  suppression  of 
bone marrow function and a thromhocytopenic crisis similar to the hemolytic crisis 
of hereditary spherocytosis  (17).  This possibility  is supported by the occurrence of 
exacerbations  of ITP after trauma as well as after infections. 
Platelets altered sufficiently by attachment of antibody to be sequestered  abnor- 
mally might stiU function effectively in hemostasis during their period of circulation. 
The possibility  exists,  however,  that attachment of special  antibodies  to platelets 
may affect their hemostatic function primarily and have relatively little effect on 
their susceptibility  to sequestration.  This may occur in certain diseases in the cate- 
gories  of  "thrombocytopathic purpuras"  and  "pseudohemophilia"  (11)  in  which 
capillary abnormalities  usually associated  with thrombocytopenia can occur in the 
presence of a normal or only slightly reduced platelet level. 
These hypotheses offer a unitary concept for the pathogenesis of a group of 
diseases  characterized by thrombocytopenia and  capillary dysfunction, and 
lend themselves readily to further experimental evaluation both in vivo and in 
vitro.  Similar mechanisms may play a  role in diseases of sensitivity involving 
other types of blood ceils. 
SUM~Y 
Regulated intravenous doses of quirddine were given to patients  with  the 
antibody of quinidine purpura to produce controlled thrombocytopenia without 
clinical sequelae. The degree of thrombocytopenia and the rate at which it de- 
veloped were dependent on the relative plasma concentration of quinidine and 
antibody. By relating in vivo changes in plateiet levels to concurrent  in vitro tests 
for antibody activity and to quantitative relationships between reactants de- 
termined in Papers I  and III of this series, it was concluded that the amount of 
antibody which attaches to platelets when thrombocytopenia develops is in- 
sufficient to cause complement fixation or platelet agglutination. Plateiets do 
not  appear  to be destroyed directly by reaction with antibody irt vivo.  The 
minimal amount of antibody which does attach to platelets in vivo appears to 
increase their susceptibility to the usual mechanisms of sequestration. N.  RAPHAEL  SHULMAN  729 
Megakaryocytes and blood vessels do not appear to be affected directly by 
the antibody which causes quinidine purpura, and hemorrhagic manifestations 
of the disease appear to be consequent to changes in platelets alone. 
A safe method of performing in vivo tests for the presence of an antibody of 
drug purpura is described. 
The implications of the present work in idiopathic thrombocytopenic purpura 
are discussed. 
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